Ian Sanne to Tuberculosis
This is a "connection" page, showing publications Ian Sanne has written about Tuberculosis.
Connection Strength
2,561
-
Impact of three empirical anti-tuberculosis treatment strategies for people initiating antiretroviral therapy. Int J Tuberc Lung Dis. 2014 Nov; 18(11):1340-6.
Score: 0,317
-
Tuberculosis in patients receiving antiretroviral treatment: incidence, risk factors, and prevention strategies. J Acquir Immune Defic Syndr. 2011 Apr; 56(4):349-55.
Score: 0,247
-
Rifapentine With and Without Moxifloxacin for Pulmonary Tuberculosis in People With Human Immunodeficiency Virus (S31/A5349). Clin Infect Dis. 2023 02 08; 76(3):e580-e589.
Score: 0,140
-
Building sustainable clinical trial sites in Sub-Saharan Africa through networking, infrastructure improvement, training and conducting clinical studies: The PanACEA approach. Acta Trop. 2023 Feb; 238:106776.
Score: 0,139
-
Adaptation of WHO's generic tuberculosis patient cost instrument for a longitudinal study in Africa. Glob Health Action. 2021 01 01; 14(1):1865625.
Score: 0,121
-
Human Immunodeficiency Virus Type 1 and Tuberculosis Coinfection in Multinational, Resource-limited Settings: Increased Neurological Dysfunction. Clin Infect Dis. 2019 05 02; 68(10):1739-1746.
Score: 0,108
-
High rates of death and loss to follow-up by 12 months of rifampicin resistant TB treatment in South Africa. PLoS One. 2018; 13(10):e0205463.
Score: 0,104
-
Does Disseminated Nontuberculous Mycobacterial Disease Cause False-Positive Determine TB-LAM Lateral Flow Assay Results? A Retrospective Review. Clin Infect Dis. 2017 10 01; 65(7):1226-1228.
Score: 0,097
-
Predictive and prognostic properties of TB-LAM among HIV-positive patients initiating ART in Johannesburg, South Africa. Pan Afr Med J. 2015; 22:4.
Score: 0,084
-
Towards host-directed therapies for tuberculosis. Nat Rev Drug Discov. 2015 Aug; 14(8):511-2.
Score: 0,083
-
Combined effect of CYP2B6 and NAT2 genotype on plasma efavirenz exposure during rifampin-based antituberculosis therapy in the STRIDE study. Clin Infect Dis. 2015 Jun 15; 60(12):1860-3.
Score: 0,081
-
Tuberculosis immune reconstitution inflammatory syndrome in A5221 STRIDE: timing, severity, and implications for HIV-TB programs. J Acquir Immune Defic Syndr. 2014 Apr 01; 65(4):423-8.
Score: 0,076
-
Identification of a 251 gene expression signature that can accurately detect M. tuberculosis in patients with and without HIV co-infection. PLoS One. 2014; 9(2):e89925.
Score: 0,075
-
Evaluation of two line probe assays for rapid detection of Mycobacterium tuberculosis, tuberculosis (TB) drug resistance, and non-TB Mycobacteria in HIV-infected individuals with suspected TB. J Clin Microbiol. 2014 Apr; 52(4):1052-9.
Score: 0,075
-
Whole-genome sequencing to establish relapse or re-infection with Mycobacterium tuberculosis: a retrospective observational study. Lancet Respir Med. 2013 Dec; 1(10):786-92.
Score: 0,074
-
Relationship between weight, efavirenz exposure, and virologic suppression in HIV-infected patients on rifampin-based tuberculosis treatment in the AIDS Clinical Trials Group A5221 STRIDE Study. Clin Infect Dis. 2013 Aug; 57(4):586-93.
Score: 0,071
-
Linkage to care and treatment for TB and HIV among people newly diagnosed with TB or HIV-associated TB at a large, inner city South African hospital. PLoS One. 2013; 8(1):e49140.
Score: 0,070
-
Antiretroviral therapy initiation during tuberculosis treatment and HIV-RNA and CD4 T-lymphocyte responses. Int J Tuberc Lung Dis. 2012 Oct; 16(10):1358-64.
Score: 0,068
-
Natural killer cell activation distinguishes Mycobacterium tuberculosis-mediated immune reconstitution syndrome from chronic HIV and HIV/MTB coinfection. J Acquir Immune Defic Syndr. 2011 Nov 01; 58(3):309-18.
Score: 0,064
-
Timing of antiretroviral therapy for HIV-1 infection and tuberculosis. N Engl J Med. 2011 Oct 20; 365(16):1482-91.
Score: 0,064
-
Efavirenz and rifampicin in the South African context: is there a need to dose-increase efavirenz with concurrent rifampicin therapy? Antivir Ther. 2011; 16(4):527-34.
Score: 0,061
-
Xpert(®) MTB/RIF for point-of-care diagnosis of TB in high-HIV burden, resource-limited countries: hype or hope? Expert Rev Mol Diagn. 2010 Oct; 10(7):937-46.
Score: 0,060
-
Prolonged deferral of antiretroviral therapy in the SAPIT trial: did we need a clinical trial to tell us that this would increase mortality? S Afr Med J. 2010 Sep 07; 100(9):566, 568, 570-1.
Score: 0,059
-
Initiating patients on antiretroviral therapy at CD4 cell counts above 200 cells/microl is associated with improved treatment outcomes in South Africa. AIDS. 2010 Aug 24; 24(13):2041-50.
Score: 0,059
-
Scale-up of services and research priorities for diagnosis, management, and control of tuberculosis: a call to action. Lancet. 2010 Jun 19; 375(9732):2179-91.
Score: 0,058
-
Tuberculosis treatment and risk of stavudine substitution in first-line antiretroviral therapy. Clin Infect Dis. 2009 Jun 01; 48(11):1617-23.
Score: 0,054
-
Opportunities and challenges for HIV care in overlapping HIV and TB epidemics. JAMA. 2008 Jul 23; 300(4):423-30.
Score: 0,051